Cystic fibrosis drug Orkambi 'too pricey for the NHS'

Cystic fibrosis drug Orkambi 'too pricey for the NHS' The National Institute for Health and Care Excellence rejected the drug, which has been shown in clinical trials to improve lung function and respiratory symptoms in people with cystic fibrosis. The Daily Mail

See also:

• Cost of cystic fibrosis treatment too high for benefit offered NICE